---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-021434"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-05-26T23:59:59+00:00"
generated_at: "2026-06-25T06:49:14.485698+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO

## Summary
- Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.
- Data from 29 patients (21 evaluable) across multiple tumor types with p53 Y220C mutation; safety profile well-tolerated.
- Dose-proportional increases in Cmax and AUC observed; updated data to be presented in oral session on June 7, 2022.
- Company to host investor webcast on June 7 at 6:30 PM CDT to review data.

## SEC filing metadata
- accession: 0001564590-22-021434
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-05-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/0001564590-22-021434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/pmvp-8k_20220526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-021434
- JSON: https://secwatch.observer/filing/0001564590-22-021434.json
- Plain text: https://secwatch.observer/filing/0001564590-22-021434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.